K. K. Ray

Type de document

Articles (3) Recensions (1)

Co-auteur

Date

Source

Mot-clé

thérapie (3) risque (3) Treatment (3) Therapeutics (3) Risk (3) Patients (3) Cholesterol (3) Patients (3) évaluation du risque (2) gestion (2) lipide (2) Europe (2) âge (2) maladie cardiovasculaire (2) abords (agglomération) (2) Europe (2) Control (2) Care (2) Risk assessment (2) Manufacturers' agents (2) Management (2) Evidence (2) Europe (2) Commission merchants (2) Atherosclerosis (2) Age (2) Management (2) Age (2) Risk assessment (2) plasma (2)

Documents écrit par K. K. Ray (3) | parle de K. K. Ray (0)

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study.
K.K. Ray et al.
Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe - Methodology and rationale for the multinational observational SANTORINI study.
K.K. Ray et al.
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
J.C. Fruchart et al. (4 juin 2019)